(PHILADELPHIA) Bracket, one of the industry’s leading eCOA solutions providers today announced that it has completed the e-Diary Certification program with Evidera™ for the EXACT patient daily e-Diary on both an Android smartphone, and an Android Tablet. The certification allows Bracket to standardize its EXACT e-Diary eCOA solution and pass valuable delivery efficiencies to clinical trial sponsors or contract research organizations (CRO). This is an important milestone as it demonstrates Bracket eCOA solution as it becomes the first and only provider of this instrument to be certified on a tablet device.
The EXACT (the EXAcerbations of Chronic pulmonary disease Tool) is a 14-item patient reported outcome (PRO) daily diary used to quantify and measure exacerbations of chronic obstructive pulmonary disease (COPD). Exacerbations are events characterized by an acute, sustained worsening in the patient’s COPD beyond normal day-to-day variability, including an increase in respiratory symptoms such as dyspnea, cough, and sputum production that may require a change in treatment. The EXACT e-Diary is designed to standardize the assessment of the patient’s condition in order to capture this dynamic process.
“Today’s eCOA landscape is very promising,” says Jim Primerano, Senior Vice President and GM, eClinical at Bracket. “The use of ePRO and eCOA solutions in clinical trials has grown in the past 2 years and Bracket sees immense value in providing validated outcomes instruments to facilitate the collection of key trial data. We are very pleased to incorporate the EXACT e-Diary into our ePRO library of instruments, extending more efficiency in delivery of eCOA solutions to our customers.”
Bracket, with seven offices and more than 500 employees worldwide, is focused on bringing together best-in-class science, technology and service to drive superior clinical outcome results for pharmaceutical companies and for patients. In August 2013, Bracket became an independent portfolio company of Parthenon Capital Partners, a Boston- and San Francisco-based growth-oriented private equity firm that provides capital and strategic resources to growing middle market companies for acquisitions and internal growth.
Evidera, a wholly owned subsidiary of Symphony Technology Group, provides health economic, outcomes research, market access, data analytic and epidemiology services to life sciences organizations worldwide. For more information, visit www.evidera.com.
For Immediate Release
September 15, 2015
Contact: Adam Butler
+1 (610) 225-5900